Annexin Pharmaceuticals
13.40 SEK
-0.74 %
Less than 1K followers
ANNX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-0.74 %
-14.10 %
-32.32 %
-32.32 %
-51.45 %
-61.38 %
-78.12 %
-85.85 %
-95.81 %
Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
94.59M SEK
Turnover
1.86K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
12/5
2026
Interim report Q1'26
12/5
2026
General meeting '26
16/7
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Redeye: Annexin Pharmaceuticals (Q4 review): Phase II study away, with positive initial results
Annexin Pharmaceuticals bokslutskommuniké 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools